The GlaxoSmithKline Pharmaceutical Limited (GSK) is one of the oldest, research based pharmaceutical company, enjoying its leadership position in the global market. After a gap of 15 years, the company is starting its first new manufacturing facility at Vemgal, Karnataka one of the state in India for that company is investing 1,000 Cr. Along with the new setup, the company is expanding its old facility as well.
According to the statement made by Ian Felton, Deputy High Commissioner, British Deputy High Commission, Bengaluru, the groundbreaking ceremony will be conducted in the month of September 8. The company will start its production in 2018, and initially, the company will supply only solid form dose products. According to the GSK’s annual report, the GSK will produce 8 billion tablets and 1 billion capsules a year. About 30 percent of the global pharmaceutical volume sold by GSK was sold in the country.”
The climatic conditions are moderate, availability of southern distribution hub and state based investment incentives and government land, easy accessibility to market these are the reasons why GSK chosen Vemgal for its new manufacturing facility.
Annaswami Vaidheesh, M.D. of GlaxoSmithKline Pharmaceutical said, “The company will focus on securing a reliable supply of high-quality medicines to patients through manufacturing facility in Nashik and an upcoming facility in Karnataka. The company will continue to bring the best of their innovative global pipeline in areas like respiratory and vaccines to patients in India.” He also said, “we fully support the government in their efforts to increase access to affordable medicines to improve healthcare and we are very excited to begin work on what will become our largest manufacturing facility in India.”
With deliberating quality products into a combative generic market, the company is trying to meet a moneymaking volume growth. The new setup of the company will create a huge platform for job seekers and helps to increase the financial status of the country.